BioSpace News Archive

Nabla Bio, a next-generation antibody design company, announced the closing of a $11M Seed financing round.

AnHeart Therapeutics Appoints Hua Zheng , M.D, Ph.D, as SVP, Head of Global Regulatory Affairs.

Agilent Technologies Inc. (NYSE: A) has announced that the Agilent Cary 3500 UV-Vis Spectrophotometer is now compatible with the Agilent OpenLab software suite of products.

POXEL SA, a clinical stage biopharmaceutical company developing innovative treatments for chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis and rare disorders, announced the formation of its Scientific Advisory Board for rare metabolic diseases.

Bavarian Nordic A/S a fully integrated vaccines company, formally announces its commitment to initiate a Phase 3 clinical trial of its RSV vaccine candidate, MVA-BN® RSV.

Calibre Scientific is pleased to announce the acquisition of Benson Polymeric, a manufacturer of polymer-based HPLC columns and resin.

OKYO Pharma Limited, the biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, is pleased to announce that working with Ora, Inc., a world-class ophthalmic clinical development partner, it is currently anticipating the filing of an IND in Q3 2022 for OK-101 in the treatment of dry eye disease.

Aran Biomedical has expanded their weaving capabilities to include the condensing of high-density woven fabric.

The 2nd R&D Day event of IMPACT Therapeutics successfully took place in Shanghai on December 3rd.

Galderma announced that the Journal of Allergy and Clinical Immunology has published gene expression data that demonstrate the positive anti-inflammatory effect and mode of action of nemolizumab in patients with moderate to severe Prurigo Nodularis, confirming the potential of nemolizumab as a major player in the treatment of PN, effectively reducing both pruritus and severity of skin lesions in PN patients.